In recent years, we’ve seen remarkable progress in combatting devastating cancers, with the rise of immunotherapies across a breadth of therapeutic modalities, from antibody-based immunomodulators to cell-based therapies to other emerging technologies. And yet, while there are more than 30 approved immunotherapies on the market today, only about 15-20% of patients respond to available treatments, demonstrating a necessity for more effective and tolerable options.
Over the past two decades, advancements in the industry have shifted how we diagnose, classify and ultimately treat certain cancers according to an individual’s molecular profile – a practice known as precision medicine. What does this transformative approach, and the diagnostics needed to achieve it, mean for the oncology industry, and most importantly, for patients with cancer? What gaps still remain, and how can stakeholders come together to address them?
Health economics (HE) analyzes the costs and consequences of healthcare interventions to evaluate their effects on patient-related clinical, humanistic, and economic outcomes.
At Takeda, we are committed to advancing the principles and practice of HE by collaborating with strategic partners to identify innovative and bold solutions that help ensure patients have access to our medicines.
After over a year and a half of working from home, I looked forward to returning to the office as part of our new hybrid working environment. I’m a people person, and I really missed the energy that comes when working with colleagues face to face.
Working Together to Create a Future Without Cancer: Takeaways from The Economist’s World Cancer Series
Earlier this month, I attended The Economist’s World Cancer Series: Europe event, which brought together leaders from across the oncology ecosystem to discuss how we can improve cancer care on a global scale.
Today’s oncology field force in the pharmaceutical industry—the people responsible for connecting patient care teams with therapeutic innovations—looks much different than it has in recent years.
I am proud of how Takeda – like so many companies around the world – has adapted and embraced new ways of working over the past year-and-a-half. As Head of Global Oncology Patient Value, Policy and Access (PVPA) at Takeda, I also miss in-person interactions with my team and colleagues and look forward to returning to the workplace soon
Unique Cancers Require a Unique Approach: Takeda’s Take on Treating Underserved Diseases at the Source
Over the past decade, cancer care has evolved significantly. Advancements in diagnostics and precision medicine have been a major contributor to this evolution, illustrating how – for certain patient populations – identifying and targeting the very source of a person’s cancer can more effectively improve outcomes compared to traditional treatment methods.
I’ve always been a firm believer in the power of personal time off. I recently went on vacation and returned feeling completely revitalized. I find that this personal time away gives me a fresh perspective, renewed energy and space to think more creatively.
As the discovery and treatment of cancer continues to evolve, comprehensive genomic profiling (CGP), using next-generation sequencing (NGS) technology, has emerged as a necessary and accessible tool for improving diagnosis.
In our time at Takeda Oncology, we’ve had the opportunity to observe how real-world evidence (RWE) obtained outside of randomized controlled trials (RCTs) has been playing an increasingly important role in understanding treatment options for patients, especially in the field of multiple myeloma research.